In patients with HER2‐negative, PD‐L1 CPS ≥ 1 gastric cancer, the addition of lenvatinib and pembrolizumab to chemotherapy failed to significantly improve OS compared to chemotherapy alone (12.6 vs. 12.9 months) [97]. This evidence concerns the gene ERBB2 and gastric cancer.